Power Law company profile

89bio

Biotech & Life Sciences · San Francisco, United States · Founded 2018 · IPO 2019 Unicorn

A biopharmaceutical company building a pipeline of biologic and small molecule treatments for liver and metabolic disorders

Valuation

$1.68B

Market cap · 2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

3 investors on 89bio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage

OrbiMed

RA Capital Management

Longitude Capital

Global footprint

Where 89bio has talent and traffic

Workforce by country

🇺🇸 United States · San Francisco HQ

Book a demo for the full country breakdown

Web traffic by country

7.5K monthly visits
across markets

🇺🇸 United States72%

🇮🇳 India21.3%

🇬🇧 United Kingdom6.7%

Top 3 markets shown

Market sentiment

What the market is saying about 89bio

An AI-synthesized read of the highest-engagement posts about 89bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See 89bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles